Table 5.
Cumulative effect of HLA match, TCE, and DP expression, model restricted to 11/12 permissive (N=166)*
| Clinical Endpoint | TCE*DP Expression | N | Events | Hazard Ratio | 95% CI | P |
|---|---|---|---|---|---|---|
| OS | PR-AA | 46 | 6 | |||
| PR-Other | 59 | 22 | 2.82 | 1.13-7.09 | 0.03 | |
| NoPR | 61 | 22 | 2.82 | 1.13-7.03 | 0.03 | |
| EFS | PR-AA | 46 | 12 | |||
| PR-Other | 59 | 24 | 1.47 | 0.74-2.95 | 0.27 | |
| NoPR | 61 | 28 | 1.80 | 0.90-3.58 | 0.10 | |
| CIR | PR-AA | 46 | 9 | |||
| PR-Other | 59 | 11 | 0.78 | 0.33-1.85 | 0.57 | |
| NoPR | 61 | 10 | 0.65 | 0.25-1.70 | 0.38 | |
| NRM | PR-AA | 46 | 3 | |||
| PR-Other | 59 | 13 | 3.47 | 1.00-12.09 | 0.05 | |
| NoPR | 61 | 18 | 5.08 | 1.51-17.08 | 0.01 | |
| Acute GvHD II-IV | PR-AA | 46 | 15 | |||
| PR-Other | 58 | 19 | 1.04 | 0.53-2.04 | 0.91 | |
| NoPR | 61 | 32 | 2.02 | 1.11 -3.68 | 0.02 | |
| Acute GvHD III-IV | PR-AA | 46 | 4 | |||
| PR-Other | 58 | 8 | 1.73 | 0.50-5.96 | 0.38 | |
| NoPR | 61 | 10 | 1.98 | 0.63-6.25 | 0.25 | |
| Chronic GvHD | PR-AA | 45 | 35 | |||
| PR-Other | 58 | 40 | 0.93 | 0.59-1.46 | 0.75 | |
| NoPR | 61 | 44 | 0.98 | 0.62-1.54 | 0.92 |
*
All models are multivariable and adjusted for age (<58 vs. ≥58) and disease risk (high, intermediate, low/non-malignant). Patients with incomplete clinical data or with disease risk of other were excluded.